73 related articles for article (PubMed ID: 10690627)
1. Characterization of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Meenakshi A; Sivakumar N; Kumar RR; Shankar SG; Dean CJ; Modjtahedi H
Hum Antibodies; 1999; 9(3):149-54. PubMed ID: 10690627
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
4. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
[TBL] [Abstract][Full Text] [Related]
5. Enzyme immunoassay of human epidermal growth factor receptor (hEGFR).
Kumar RR; Meenakshi A; Sivakumar N
Hum Antibodies; 2001; 10(3-4):143-7. PubMed ID: 11847425
[TBL] [Abstract][Full Text] [Related]
6. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
Meenakshi A; Kumar RS; Kumar NS
Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
8. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
9. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
11. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
12. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
13. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
[TBL] [Abstract][Full Text] [Related]
14. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
[TBL] [Abstract][Full Text] [Related]
15. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
16. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
17. Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells.
Rezaiemanesh A; Majidi J; Baradaran B; Movasaghpour A; Nakhlband A; Barar J; Omidi Y
Hum Antibodies; 2010; 19(2-3):63-70. PubMed ID: 20826931
[TBL] [Abstract][Full Text] [Related]
18. Are epidermal growth factor and transforming growth factor responsible for pseudoepitheliomatous hyperplasia associated with granular cell tumors?
Barkan GA; Paulino AF
Ann Diagn Pathol; 2003 Apr; 7(2):73-7. PubMed ID: 12715330
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185.
Meenakshi A; Kumar RS; Ganesh V; Sivakumar N
Hum Antibodies; 2003; 12(4):123-7. PubMed ID: 15156100
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression.
Fantozzi I; Grall D; Cagnol S; Stanchi F; Sudaka A; Brunstein MC; Bozec A; Fischel JL; Milano G; Van Obberghen-Schilling E
Acta Oncol; 2008; 47(8):1502-12. PubMed ID: 18607838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
